Cancer patients desperate to buy themselves more time are spending thousands of dollars to self-fund immunotherapy treatment even though there is little evidence to show it is likely to have a major benefit. A retrospective review describing outcomes and toxicity of self-funded pembrolizumab in patients with non-melanoma solid cancers at Chris O’Brien Lifehouse has followed ...
Desperate cancer patients prepared to pay for immunotherapy treatment
By Amanda Sheppeard
2 Sep 2016